Disease relevance of chlormezanone

• The use of antibacterial sulfonamides, anticonvulsant agents, oxicam NSAIDs, allopurinol, chlormezanone, and corticosteroids is associated with large increases in the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis [1].
• Chlormezanone may possibly be a valuable addition to antiemetic and analgesic therapy of migraine attacks [2].
• Fixed drug eruption caused by chlormezanone [3].
• Additionally, chlormezanone plasma levels were determined after repeated oral doses of chlormezanone recommended for treatment of muscular spasms due to degenerative skeletal disease [4].
• Chlormezanone in primary fibromyalgia syndrome: a double blind placebo controlled study [5].

Psychiatry related information on chlormezanone

• There was no obvious evidence of chlormezanone causing an impairment in early morning psychomotor performance, car driving ability or subjective ratings of early morning behaviour [6].

High impact information on chlormezanone

• The enzyme was strongly inhibited in vitro by high concentrations of paracetamol and chlormezanone [7].
• Relative bioavailability of 3 different chlormezanone 200 mg preparations after single dose oral administration [8].
• The case of a 29 year old woman affected by fulminant hepatitis during the third trimester of pregnancy, after a 3 week administration of chlormezanone is reported [9].
• Pharmacokinetics of chlormezanone in elderly patients [10].
• A double-blind, crossover, multi-centre study was carried out in general practice on 76 patients with mild neurotic anxiety and associated sleep disturbance to compare the effectiveness of chlormezanone given as a single night-time dose of 200 mg or 400 mg, each given for a period of 1 week [11].

Chemical compound and disease context of chlormezanone

• A patient-assessment of pain relief over 4 hours following a single dose of a compound analgesic has shown that 78% of patients achieve satisfactory relief of pain due to tension headache and that this response is enhanced by the addition of chlormezanone, an agent with reported anxiolytic and muscle relaxant actions [12].
• Four hundred patients with painful muscle spasm caused by five common musculoskeletal diseases were included in a double-blind controlled trial of chlormezanone, orphenadrine, orphenadrine/paracetomol and placebo [13].
• Toxic epidermal necrolysis with epidermal shedding over almost the entire body occurred in a patient with classical rheumatoid arthritis treated with sulindac, penicillamine and a combination analgesic containing paracetamol and chlormezanone [14].

Biological context of chlormezanone

• An open assessment of chlormezanone in the treatment of rheumatic sleep disturbances was carried out in general practice [15].
• Biotransformation of chlormezanone, 2-(4-chlorophenyl)-3-methyl-4-metathiazanone-1,1-dioxide, a muscle-relaxing and tranquillizing agent: the effect of combination with aspirin on its metabolic fate in rats and mice [16].
• One group of patients (n = 23) were treated with laser acupuncture (5 mW HeNe laser on 22 acupuncture points for 15 s each) plus cervical collar and a combination of paracetamol and chlormezanone; a second group (n = 22) received the same treatments but with the use of a placebo laser [17].

Anatomical context of chlormezanone

• Interaction of chlormezanone with rat liver microsomes and its degradation [18].
• There was no stimulation of sulfidoleukotrienes in human leukocytes by chlormezanone [19].
• Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro [19].

Associations of chlormezanone with other chemical compounds

• A multi-centre, double-blind trial was carried out in general practice in 44 patients with symptoms of neurotic anxiety to compare the effects of treatment with either 400 mg chlormezanone at night or 5 mg diazepam 3-times daily for 4 weeks [20].
• Chlormezanone binds to oxidized cytochrome P450 in rat liver microsomes with a binding curve according to type I like hexobarbital but less pronounced and with a general shift to the left [18].

Analytical, diagnostic and therapeutic context of chlormezanone

• Sensitive and selective method for the determination of chlormezanone in plasma by electron-capture gas chromatography [21].
• Plasma concentrations of chlormezanone were determined by a validated reversed-phase HPLC method with UV detection, with a lower limit of quantification of 0.1 microgram/ml [8].
• Chlormezanone-induced fulminant hepatitis in a pregnant woman: successful delivery and liver transplantation [9].
• Chlormezanone plasma concentrations were determined in 5 volunteers (group 1) after a single oral dose of 200 mg of chlormezanone with high performance liquid chromatography [4].
• Patch tests were performed in a suspected case of FDE due to chlormezanone on the patient's normal and prelesional skin with all ingested drugs whose concentrations were one and ten percent [22].

References